Treatment of NSCLC patients with antibodies targeting CTLA-4 (e.g., ipilumumab) in conjunction with chemotherapy results in modest increases in immune-related, progression-free survival, but overall survival is unchanged [14]. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.